Alexander Colevas

Publications

• Biased View of the Role of Site-Specific Therapy in Carcinoma of Unknown Primary. Percival ME, Colevas AD. J Clin Oncol. 2013
• Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential. LoRusso PM, Piha-Paul SA, Mita M, Colevas AD, Malhi V, Colburn D, Yin M, Low JA, Graham RA. Cancer Chemother Pharmacol. 2013; 71 (1): 193-202
• Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Ho AS, Tsao GJ, Chen FW, Shen T, Kaplan MJ, Colevas AD, Fischbein NJ, Quon A, Le QT, Pinto HA, Fee WE, Sunwoo JB, Sirjani D, Hara W, Yao M. Cancer. 2013; 119 (7): 1349-56
• Long-term outcomes of surgery followed by radiation therapy for minor salivary gland carcinomas. Zeidan YH, Shultz DB, Murphy JD, An Y, Chan C, Kaplan MJ, Colevas AD, Kong C, Chang DT, Le QT. Laryngoscope. 2013
• Population-based evaluation of incidence trends in oropharyngeal cancer focusing on socioeconomic status, sex, and race/ethnicity. Colevas AD, Head Neck. 2013
• Stereotactic radiosurgery for retreatment of gross perineural invasion in recurrent cutaneous squamous cell carcinoma of the head and neck. Tang C, Fischbein NJ, Murphy JD, Chu KP, Bavan B, Dieterich S, Hara W, Kaplan MJ, Colevas AD, Le QT. Am J Clin Oncol. 2013; 36 (3): 293-8
• A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. Bible KC, Peethambaram PP, Oberg AL, Maples W, Groteluschen DL, Boente M, Burton JK, Gomez Dahl LC, Tibodeau JD, Isham CR, Maguire JL, Shridhar V, Kukla AK, Voll KJ, Mauer MJ, Colevas AD, Wright J, Doyle LA, Erlichman C. Gynecol Oncol. 2012; 127 (1): 55-62
• A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. Padda SK, Krupitskaya Y, Chhatwani L, Fisher GA, Colevas AD, San Pedro-Salcedo M, Decker R, Latz JE, Wakelee HA. Cancer Chemother Pharmacol. 2012; 69 (4): 1013-20
• A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. Diaz-Padilla I, Siu LL, San Pedro-Salcedo M, Razak AR, Colevas AD, Shepherd FA, Leighl NB, Neal JW, Thibault A, Liu L, Lisano J, Gao B, Lawson EB, Wakelee HA. Br J Cancer. 2012; 107 (4): 604-11
• A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Kim KB, Prieto V, Joseph RW, Diwan AH, Gallick GE, Papadopoulos NE, Bedikian AY, Camacho LH, Hwu P, Ng CS, Wei W, Johnson MM, Wittemer SM, Vardeleon A, Reckeweg A, Colevas AD. Melanoma Res. 2012; 22 (4): 294-301
• Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lee NY, Zhang Q, Pfister DG, Kim J, Garden AS, Mechalakos J, Hu K, Le QT, Colevas AD, Glisson BS, Chan AT, Ang KK. Lancet Oncol. 2012; 13 (2): 172-80
• Intensity-modulated radiotherapy for tumors of the nasal cavity and paranasal sinuses: clinical outcomes and patterns of failure. Wiegner EA, Daly ME, Murphy JD, Abelson J, Chapman CH, Chung M, Yu Y, Colevas AD, Kaplan MJ, Fischbein N, Le QT, Chang DT. Int J Radiat Oncol Biol Phys. 2012; 83 (1): 243-51
• Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer. Riess JW, Logan AC, Krupitskaya Y, Padda S, Clément-Duchêne C, Ganjoo K, Colevas AD, Pedro-Salcedo MS, Kuo CJ, Wakelee HA. Cancer Invest. 2012; 30 (3): 231-5
• Mucosal melanoma of the head and neck. Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf G, Worden F. J Natl Compr Canc Netw. 2012; 10 (3): 320-38
• Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. Kunz PL, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, Marshall JL. Invest New Drugs. 2012; 30 (6): 2364-70
• Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Douglas Figg W, Karp JE, Koc ON, Cooper BW, Luger SM, Colevas AD, Roberts JD, Grant S. Cancer Chemother Pharmacol. 2012; 69 (6): 1657-67
• Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, Stockdale FE, Mollick JA, Chen L, Levy R. J Clin Invest. 2012; 122 (3): 1066-75
• The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck. Russell JS, Colevas AD. Chemother Res Pract. 2012: 2012 761518
• Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. Trakul N, Chang CN, Harris J, Chapman C, Rao A, Shen J, Quinlan-Davidson S, Filion EJ, Wakelee HA, Colevas AD, Whyte RI, Dieterich S, Maxim PG, Hristov D, Tran P, Le QT, Loo BW, Diehn M. Int J Radiat Oncol Biol Phys. 2012; 84 (1): 231-7
• Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Tang C, Murphy JD, Khong B, La TH, Kong C, Fischbein NJ, Colevas AD, Iagaru AH, Graves EE, Loo BW, Le QT. Int J Radiat Oncol Biol Phys. 2012; 83 (5): 1514-20
• Controversies in the locoregional management of head and neck cancer. Brizel DM, Lydiatt W, Colevas AD. J Natl Compr Canc Netw. 2011; 9 (6): 653-62
• Head and neck cancers. Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf GT, Worden F. J Natl Compr Canc Netw. 2011; 9 (6): 596-650
• Intensity-modulated radiotherapy for locally advanced cancers of the larynx and hypopharynx. Daly ME, Le QT, Jain AK, Maxim PG, Hsu A, Loo BW, Kaplan MJ, Fischbein NJ, Colevas AD, Pinto H, Chang DT. Head Neck. 2011; 33 (1): 103-11
• A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. Clément-Duchêne C, Krupitskaya Y, Ganjoo K, Lavori P, McMillan A, Kumar A, Zhao G, Padda S, Zhou L, Pedro-Salcedo MS, Colevas AD, Wakelee HA. J Thorac Oncol. 2010; 5 (11): 1821-5
• Higher incidence of head and neck cancers among Vietnamese American men in California. Filion EJ, McClure LA, Huang D, Seng K, Kaplan MJ, Colevas AD, Gomez SL, Chang ET, Le QT. Head Neck. 2010; 32 (10): 1336-44
• Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer. Van Waes C, Allen CT, Citrin D, Gius D, Colevas AD, Harold NA, Rudy S, Nottingham L, Muir C, Chen Z, Singh AK, Dancey J, Morris JC. Int J Radiat Oncol Biol Phys. 2010; 77 (2): 447-54
• Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer. Citrin D, Mansueti J, Likhacheva A, Sciuto L, Albert PS, Rudy SF, Cooley-Zgela T, Cotrim A, Solomon B, Colevas AD, Russo A, Morris JC, Herscher L, Smith S, Van Waes C. Int J Radiat Oncol Biol Phys. 2009; 74 (4): 1040-6
• A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma. O'Connor OA, Portlock C, Moskowitz C, Straus D, Hamlin P, Stubblefield M, Dumetrescu O, Colevas AD, Grant B, Zelenetz A. Br J Haematol. 2008; 143 (2): 201-9
• Head and neck cancers. Forastiere AA, Ang KK, Brizel D, Brockstein BE, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Goepfert H, Hicks WL, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pfister DG, Pinto HA, Posner MR, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf GT, Worden F. J Natl Compr Canc Netw. 2008; 6 (7): 646-95
• Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Tang PA, Siu LL, Chen EX, Hotte SJ, Chia S, Schwarz JK, Pond GR, Johnson C, Colevas AD, Synold TW, Vasist LS, Winquist E. Invest New Drugs. 2008; 26 (3): 257-64
• A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Hensley ML, Dizon D, Derosa F, Venkatraman E, Sabbatini P, Chi DS, Dupont J, Colevas AD, Spriggs D, Aghajanian C. Invest New Drugs. 2007; 25 (4): 335-41
• A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Posadas EM, Undevia S, Manchen E, Wade JL, Colevas AD, Karrison T, Vokes EE, Stadler WM. Cancer Biol Ther. 2007; 6 (4): 490-3
• Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM, Haddad RI. N Engl J Med. 2007; 357 (17): 1705-15
• Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez JR, Colevas AD, Grever MR. Blood. 2007; 109 (2): 399-404
• Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, Wang H, Sandler A, Johnson DH, Colevas AD, Low J, Rothenberg ML, Lu B. Clin Cancer Res. 2007; 13 (10): 3033-42
• Patient-reported outcomes and the evolution of adverse event reporting in oncology. Trotti A, Colevas AD, Setser A, Basch E. J Clin Oncol. 2007; 25 (32): 5121-7
• Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD, Grossman SA. J Clin Oncol. 2007; 25 (13): 1651-7
• Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. Messersmith WA, Rudek MA, Baker SD, Zhao M, Collins C, Colevas AD, Donehower RC, Carducci MA, Wolff AC. Eur J Cancer. 2007; 43 (1): 78-86
• Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Karp JE, Smith BD, Levis MJ, Gore SD, Greer J, Hattenburg C, Briel J, Jones RJ, Wright JJ, Colevas AD. Clin Cancer Res. 2007; 13 (15 Pt 1): 4467-73
• Adverse event reporting in publications compared with sponsor database for cancer clinical trials. Scharf O, Colevas AD. J Clin Oncol. 2006; 24 (24): 3933-8
• Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Colevas AD, J Clin Oncol. 2006; 24 (17): 2644-52
• Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Beekman KW, Colevas AD, Cooney K, Dipaola R, Dunn RL, Gross M, Keller ET, Pienta KJ, Ryan CJ, Smith D, Hussain M. Clin Genitourin Cancer. 2006; 4 (4): 299-302
• In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent. Rudek MA, Zhao M, Smith NF, Robey RW, He P, Hallur G, Khan S, Hidalgo M, Jimeno A, Colevas AD, Messersmith WA, Wolff AC, Baker SD. Clin Cancer Res. 2005; 11 (23): 8503-11
• Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. Hussain M, Tangen CM, Lara PN, Vaishampayan UN, Petrylak DP, Colevas AD, Sakr WA, Crawford ED. J Clin Oncol. 2005; 23 (34): 8724-9
• Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK. J Clin Oncol. 2005; 23 (7): 1439-46
• Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, Greer J, Briel J, Smith BD, Gore SD, Tidwell ML, Ross DD, Wright JJ, Colevas AD, Bauer KS. Clin Cancer Res. 2005; 11 (23): 8403-12
• Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. Amrein PC, Clark JR, Supko JG, Fabian RL, Wang CC, Colevas AD, Posner MR, Deschler DG, Rocco JW, Finkelstein DM, McIntyre JF. Cancer. 2005; 104 (7): 1418-27
• Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent. Colevas AD, Scharf O, Schoenfeldt M. Oncology (Williston Park). 2004; 18 (14): 1778, 1781-2, 1784
• HER2 expression in salivary gland carcinomas: dependence on histological subtype. Glisson B, Colevas AD, Haddad R, Krane J, El-Naggar A, Kies M, Costello R, Summey C, Arquette M, Langer C, Amrein PC, Posner M. Clin Cancer Res. 2004; 10 (3): 944-6
• Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I, Ernst DS, Walsh W, Wainman N, Colevas AD, Eisenhauer EA. Invest New Drugs. 2004; 22 (3): 315-22
• CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P. Semin Radiat Oncol. 2003; 13 (3): 176-81
• Development of investigational radiation modifiers. Colevas AD, Brown JM, Hahn S, Mitchell J, Camphausen K, Coleman CN. J Natl Cancer Inst. 2003; 95 (9): 646-51
• Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C, Norris CM, Lake-Willcutt B, Case MA, Costello R, Posner M. Cancer. 2003; 97 (2): 412-8
• Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amrein PC, Weeks L, Costello R, Posner M. Oral Oncol. 2003; 39 (7): 724-7
• Organ preservation-induction chemotherapy. Colevas AD, Cancer Treat Res. 2003: 114 213-34
• Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial. Karp JE, Ross DD, Yang W, Tidwell ML, Wei Y, Greer J, Mann DL, Nakanishi T, Wright JJ, Colevas AD. Clin Cancer Res. 2003; 9 (1): 307-15
• A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Tishler RB, Norris CM, Colevas AD, Lamb CC, Karp D, Busse PM, Nixon A, Frankenthaler R, Lake-Willcutt B, Costello R, Case M, Posner MR. Cancer. 2002; 95 (7): 1472-81
• Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Colevas AD, Norris CM, Tishler RB, Lamb CC, Fried MP, Goguen LA, Gopal HV, Costello R, Read R, Adak S, Posner MR. Am J Clin Oncol. 2002; 25 (2): 153-9
• A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck. Colevas AD, Amrein PC, Gomolin H, Barton JJ, Read RR, Adak S, Benner S, Costello R, Posner MR. Cancer. 2001; 92 (2): 326-31
• Clinical trials referral resource. Current clinical trials of epothilone B analog (BMS-247550). Colevas AD, West PJ, Cheson BD. Oncology (Williston Park). 2001; 15 (9): 1168-9, 1172-5
• Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck. Colevas AD, Read R, Thornhill J, Adak S, Tishler R, Busse P, Li Y, Posner M. Int J Radiat Oncol Biol Phys. 2001; 51 (3): 599-604
• Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. Posner MR, Glisson B, Frenette G, Al-Sarraf M, Colevas AD, Norris CM, Seroskie JD, Shin DM, Olivares R, Garay CA. J Clin Oncol. 2001; 19 (4): 1096-104
• A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck. Colevas AD, Adak S, Amrein PC, Barton JJ, Costello R, Posner MR. Ann Oncol. 2000; 11 (5): 535-9
• NCCN Practice Guidelines for Head and Neck Cancers. Pfister DG, Ang K, Brockstein B, Colevas AD, Ellenhorn J, Goepfert H, Hicks WL, Hong WK, Kies MS, Lydiatt W, McCaffrey T, Mittal BB, Ridge JA, Schuller DE, Shah JP, Spencer S, Trotti A, Urba S, Weymuller EA, Wheeler RH, Wolf GT. Oncology (Williston Park). 2000; 14 (11A): 163-94
• The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Posner MR, Colevas AD, Tishler RB. Semin Oncol. 2000; 27 (4 Suppl 8): 13-24
• An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. Tishler RB, Busse PM, Norris CM, Rossi R, Poulin M, Thornhill L, Costello R, Peters ES, Colevas AD, Posner MR. Int J Radiat Oncol Biol Phys. 1999; 43 (5): 1001-8
• Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. Colevas AD, Norris CM, Tishler RB, Fried MP, Gomolin HI, Amrein P, Nixon A, Lamb C, Costello R, Barton J, Read R, Adak S, Posner MR. J Clin Oncol. 1999; 17 (11): 3503-11
• Re: "Sialadenosis: a presenting sign in Bulemia" (Head and Neck 20: 758-762, 1998) Colevas AD, Head Neck. 1999; 21 (6): 582
• Docetaxel in head and neck cancer: a review. Colevas AD, Posner MR. Am J Clin Oncol. 1998; 21 (5): 482-6
• Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. Colevas AD, Busse PM, Norris CM, Fried M, Tishler RB, Poulin M, Fabian RL, Fitzgerald TJ, Dreyfuss A, Peters ES, Adak S, Costello R, Barton JJ, Posner MR. J Clin Oncol. 1998; 16 (4): 1331-9
• Intramucosal spread of malignant melanoma of the oral cavity. Bhattacharyya N, Norris CM, Colevas AD, Chasse TA. Otolaryngol Head Neck Surg. 1998; 119 (6): 711
• The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck. Posner MR, Johnston PG, Tishler RB, Andersen J, Fiorentino M, Busse PM, Cavacini LA, Colevas AD, Clark J, Norris CM. Oncologist. 1998; 3 (6): 424-431
• Future directions in the treatment of squamous cell carcinoma of the head and neck: the role of UFT. Colevas AD, Oncology (Williston Park). 1997; 11 (9 Suppl 10): 86-9